# Mesoblast completes dosing in 350-patient back-pain Phase 3 trial

_Wednesday, August 19, 2026 at 3:02 AM EDT · Science · Latest · Tier 2 — Notable_

![Mesoblast completes dosing in 350-patient back-pain Phase 3 trial — Primary](https://assets.newatlas.com/dims4/default/28eb8b0/2147483647/strip/true/crop/2000x1050+0+88/resize/1200x630!/quality/90/?url=https%3A%2F%2Fnewatlas-brightspot.s3.ap-southeast-2.amazonaws.com%2F8e%2F03%2F3b3ba4ab461d96c987a379d20c04%2Fdepositphotos-349126404-l.jpg&na.image_optimisation=0)

Mesoblast has completed the patient-treatment stage of its Phase 3 trial of rexlemestrocel-L for chronic low back pain, according to New Atlas. The trial enrolled 350 people, expanded from 300, with half receiving a single intra-discal injection and half a sham control shot. Its primary endpoint is long-term pain reduction after 12 months; the article says results are expected by mid-2027. The experimental therapy is intended to treat pain associated with degenerative disc disease.

## Sources

- [New Atlas: Technology-Innovation-Outdoor News](https://newatlas.com/chronic-pain/promising-one-shot-low-back-pain-drug/)

---
Canonical: https://techandbusiness.org/newswire/CQ00XUAshg_7s3LqdY5xbm
Retrieved: 2026-08-19T10:09:35.006Z
Publisher: Tech & Business (techandbusiness.org)